GenSight will participate to the Mitochondrial Medicine 2019, annual symposium organized by The United Mitochondrial Disease Foundation (UMDF) in Washington DC from June 26 to 29, 2019.

GenSight will present a poster during the symposium on 72-week results from REVERSE Phase 3 clinical trial of GS010, our most advanced gene therapy to treat LHON, a rare mitochondrial disease affecting young people by causing a painless brutal & sequential loss of vision leading to blindness in less than a year.

  • Title: rAAV2/2-ND4 For the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial
  • Presenter:  Julio Benedicto, Vice-President, Marketing